Alembic Pharmaceuticals is currently trading at Rs. 591.50, up by 3.70 points or 0.63% from its previous closing of Rs. 587.80 on the BSE.
The scrip opened at Rs. 595.20 and has touched a high and low of Rs. 603.00 and Rs. 590.00 respectively. So far 1315 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 664.00 on 27-Sep-2018 and a 52 week low of Rs. 412.40 on 24-May-2018.
Last one week high and low of the scrip stood at Rs. 612.75 and Rs. 576.15 respectively. The current market cap of the company is Rs. 11169.57 crore.
The promoters holding in the company stood at 72.96%, while Institutions and Non-Institutions held 15.05% and 11.99% respectively.
Alembic Pharmaceuticals has reported a rise of 31.86% in its net profit at Rs 138.51 crore for the quarter ended December 31, 2018 as compared to Rs 105.04 crore for the same quarter in the previous year. Total income of the company increased by 20.24% at Rs 908.08 crore for Q3FY19 as compared Rs 755.23 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported a rise of 30.04% in its net profit at Rs 169.83 crore for the quarter under review as compared to Rs 130.60 crore for the same quarter in the previous year. Total income of the company increased by 21.58% at Rs 1021.67 crore for Q3FY19 as compared Rs 840.34 crore for the corresponding quarter previous year.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1520.55 |
Dr. Reddys Lab | 6217.15 |
Cipla | 1405.40 |
Zydus Lifesciences | 953.50 |
Lupin | 1589.10 |
View more.. |